REGENERON PHARMACEUTICALS INC Form SC 13G/A February 04, 2009

## **UNITED STATES**

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **SCHEDULE 13G**

**Under the Securities Exchange Act of 1934** 

(Amendment No. 1)\*

Regeneron Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value

(Title of Class of Securities)

75886F107

(CUSIP Number)

December 31, 2008

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

" Rule 13d-1(b)

x Rule 13d-1(c)

" Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8 pages

CUSIP No. 75886F107

1. Names of Reporting Persons.

### **QVT Financial LP**

I.R.S. Identification Nos. of above persons (entities only).

### 11-3694008

### 2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) "

(b) x 3. SEC Use Only

4. Citizenship or Place of Organization

Delaware

5. Sole Voting Power

Number of

		0
Shares	6.	Shared Voting Power

Beneficially

Owned by		2,035,975
Each	7.	Sole Dispositive Power

Reporting

Person 0 8. Shared Dispositive Power With:

### 2,035,975

9. Aggregate Amount Beneficially Owned by Each Reporting Person

### 2,035,975

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

2.63%

12. Type of Reporting Person (See Instructions)

PN

Page 2 of 8 pages

...

CUSIP No. 75886F107

1. Names of Reporting Persons.

## **QVT Financial GP LLC**

I.R.S. Identification Nos. of above persons (entities only).

### 11-3694007

### 2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) "

(b) x 3. SEC Use Only

4. Citizenship or Place of Organization

Delaware

5. Sole Voting Power

Number of

		0
Shares	6.	Shared Voting Power

Beneficially

Owned by		2,035,975
Each	7.	Sole Dispositive Power

Reporting

Person 0 8. Shared Dispositive Power With:

### 2,035,975

9. Aggregate Amount Beneficially Owned by Each Reporting Person

### 2,035,975

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

2.63%

12. Type of Reporting Person (See Instructions)

00

Page 3 of 8 pages

...

Item 1 (a). Name of Issuer   Regeneron Pharmaceuticals, Inc. (the Issuer )   Item 1 (b). Address of Issuer s Principal Executive Offices   The address of the Issuer s principal executive offices is:   777 OLLS MULD:   Description   777 OLLS MULD:   Description   777 OLLS	
Item 1 (b). Address of Issuer s Principal Executive Offices   The address of the Issuer s principal executive offices is:	
The address of the Issuer s principal executive offices is:	
777 Old Saw Mill River Road, Tarrytown, New York 10591, United States	
Item 2 (a). Name of Person Filing	
Item 2 (b). Address of Principal Business Office or, if none, Residence	
Item 2 (c). Citizenship	
QVT Financial LP	
1177 Avenue of the Americas, 9th Floor	
New York, New York 10036	
Delaware Limited Partnership	
QVT Financial GP LLC	
1177 Avenue of the Americas, 9th Floor	
New York, New York 10036	
Delaware Limited Liability Company	
Item 2 (d). Title of Class of Securities	
Common Stock, \$0.001 par value (the Common Stock ).	
Item 2 (e). CUSIP Number	
The CUSIP number of the Common Stock is 75886F107.	
Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the p	person filing is a:
(a) "Broker or dealer registered under section 15 of the Act (15 U.S.C. 780).	
(b) "Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).	
(c) "Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).	
(d) "Investment company registered under section 8 of the Investment Company Act of 194 80a-8).	40 (15 U.S.C.
(e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);	
	i)(F);
(f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii	

Page 4 of 8 pages

- (h) " A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) " A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) " A non-U.S. institution in accordance with §240.13d 1(b)(1)(ii)(J);
- (k) "Group, in accordance with §240.13d 1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d 1(b)(1)(ii)(J), please specify the type of institution:

#### Item 4. Ownership.

(a) Amount beneficially owned:

QVT Financial LP (QVT Financial) is the investment manager for QVT Fund LP (the Fund), which beneficially owns 1,834,007 shares of Common Stock. QVT Financial is the investment manager for Quintessence Fund L.P. (Quintessence), which beneficially owns 201,968 shares of Common Stock. QVT Financial has the power to direct the vote and disposition of the Common Stock held by each of the Fund and Quintessence. Accordingly, QVT Financial may be deemed to be the beneficial owner of an aggregate amount of 2,035,975 shares of Common Stock, consisting of the shares owned by the Fund and Quintessence.

QVT Financial GP LLC, as General Partner of QVT Financial, may be deemed to beneficially own the same number of shares of Common Stock reported by QVT Financial.

Each of QVT Financial and QVT Financial GP LLC disclaim beneficial ownership of the shares of Common Stock beneficially owned by the Fund and Quintessence.

The percentage disclosed in Item 11 of the Cover Pages for each reporting person is calculated based upon 77,392,971 shares of Common Stock outstanding, which is the total number of shares issued and outstanding as reported in the Issuer s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 and filed with the Securities and Exchange Commission on November 5, 2008.

(b) Percent of class:

See Item 11 of the Cover Pages to this Schedule 13G.

- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote

0

(ii) Shared power to vote or to direct the vote

See item (a) above.

(iii) Sole power to dispose or to direct the disposition of

0

Page 5 of 8 pages

(iv) Shared power to dispose or to direct the disposition of

See item (a) above.

### Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

### Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable

### Item 8. Identification and Classification of Members of the Group

Not Applicable

#### Item 9. Notice of Dissolution of Group

Not Applicable

### Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 6 of 8 pages

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 2, 2008

### QVT FINANCIAL LP

By QVT Financial GP LLC, its General Partner

By: /s/ Oren Eisner Name: Oren Eisner Title: Authorized Signatory

### **QVT FINANCIAL GP LLC**

By: /s/ Oren Eisner Name: Oren Eisner Title: Authorized Signatory

Page 7 of 8 pages

### EXHIBIT A

### JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G filed herewith (and any amendments thereto) signed by each of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: February 2, 2008

### QVT FINANCIAL LP

By QVT Financial GP LLC, its General Partner

By: /s/ Oren Eisner Name: Oren Eisner Title: Authorized Signatory

### **QVT FINANCIAL GP LLC**

By: /s/ Oren Eisner Name: Oren Eisner Title: Authorized Signatory

Page 8 of 8 pages